Developing microbiome-directed therapeutics for treating childhood undernutrition

Developing microbiome-directed therapeutics for treating childhood undernutrition

Abstract

This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.

Learning objectives

This 1-hour talk covers how researchers are testing the hypothesis that perturbations in the normal development of the gut microbiome are causally related to childhood undernutrition, a devastating global health problem whose long-term sequelae include metabolic and immune dysfunction, stunting, and neurodevelopmental abnormalities, which remains largely refractory to current therapeutic interventions.

  • Understand evidence that impaired postnatal development of the gut microbiota is causally related to childhood undernutrition
  • Understand how preclinical gnotobiotic animal models can be used to develop new microbiota-directed therapeutics
  • Understand how multiomic methods, including SomaScan® Assay proteomics, can be used to judge the efficacy and mechanism of action of these therapeutics in clinical studies

JG-picture-1-300x300-1

Jeffrey Gordon, MD

Director, Edison Family Center for Genome Sciences and Systems Biology, Washington University

MB-picture-1-300x300-1

Michael J. Barratt, PhD

Executive Director, Center for Gut Microbiome and Nutrition Research, Washington University

 

Developing microbiome-directed therapeutics for treating childhood undernutrition

A webinar presented by Jeffrey Gordon, MD, and Michael J. Barratt, PhD

Request more information

Contact us

Share with colleagues

More webinars

WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease 

Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.

Learn more

WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies 

High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.

Learn more

WebinarDetecting growing tumors through changes in the plasma proteome 

In this GEN webinar, Nebojsa Janjic, PhD, will discuss the need for a reliable blood-based screening method capable of detecting cancers earlier. During the webinar, he will highlight results from a study involving researchers from SomaLogic and the University of Colorado School of Medicine that used a test capable of measuring 5000 proteins simultaneously.

Learn more

Explore webinars in our interactive viewer